Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer is a research paper published in Cancer Immunology Immunotherapy (2023). On theSindex it has a DataRank of 0.809. It has been cited 22 times, with 22 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.470
From this paper's citation signal
Citation Network Contribution
0.339
From 17 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 22 citers.
National Institutes of Health
Grant: RO1CA206911
NCI NIH HHS
Grant: R01 CA206911
NCI NIH HHS
Grant: P30 CA033572
National Institutes of Health
Grant: 5P30CA033572-27
Developmental Funds
National Institutes of Health
Grant: 1R01CA206911-01A1
Targeting Chemotherapy-induced Breast Cancer Stemness
Cedars-Sinai Medical Center
Circle 1500
FWCI
2.50
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals